In this regard, recent studies have reported that LOX inhibition suppresses lung metastasis [24] and further provides a pre-clinical rationale for using LOX inhibitors to potentiate chemotherapy responses in terminal cancers such as pancreatic cancer [25] and triple negative breast cancer [26]. The gene discussed is LOX; the disease is familial pancreatic carcinoma.